v3.25.2
Cover Page
 12 Months Ended
Apr. 30, 2025
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Apr. 30, 2025
Document Fiscal Year Focus 2025
Document Transition Report false
Document Shell Company Report false
Document Fiscal Period Focus FY
Entity Filer Category Non-accelerated Filer
Entity Registrant Name ImmunoPrecise Antibodies Ltd.
Entity Central Index Key 0001715925
Entity File Number 001-39530
Entity Shell Company false
Entity Voluntary Filers No
Current Fiscal Year End Date --04-30
Document Accounting Standard International Financial Reporting Standards
Entity Incorporation, State or Country Code A1
Entity Current Reporting Status Yes
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Address, Address Line One Industrious 823 Congress Ave Suite 300
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78701
Entity Address, Country US
Entity Well-known Seasoned Issuer No
Title of 12(b) Security Common Shares, no par value
Trading Symbol IPA
Security Exchange Name NASDAQ
Entity Common Stock, Shares Outstanding 46,154,118
Entity Interactive Data Current Yes
ICFR Auditor Attestation Flag false
Document Financial Statement Error Correction [Flag] false
Document Annual Report true
Document Registration Statement false
Auditor Opinion [Text Block]

Opinion on the financial statements

We have audited the accompanying consolidated balance sheets of Immuno Precise Antibodies Ltd. (a British Columbia limited company) and subsidiaries (the “Company”) as of April 30, 2025 and 2024, the related consolidated statements of comprehensive loss, changes in shareholders’ equity, and cash flows for each of the three years in the period ended April 30, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended April 30, 2025, in conformity with Financial Reporting Standards as issued by the International Standards Board.
Auditor Name Grant Thornton LLP
Auditor Firm ID 248
Auditor Location Houston, Texas
Business Contact [Member]  
Document Information [Line Items]  
Contact Personnel Name Joseph Scheffler,
Entity Address, Address Line One Industrious 823 Congress Ave Suite 300
Entity Address, City or Town Austin
Entity Address, State or Province TX
Contact Personnel Email Address jscheffler@ipatherapeutics.com
Entity Address, Postal Zip Code 78701
Entity Address, Country US
City Area Code 250
Local Phone Number 483-0308